Filing Flows › Vivos Therapeutics (VVOS) › Q2 2026 › vs Q2 2025
Vivos Therapeutics (VVOS) Q2 2026 vs Q2 2025 (year over year)
Vivos Therapeutics's revenue rose $1.3M (+35%) from $3.8M in Q2 2025 to $5.2M in Q2 2026. The biggest changes: Product −$594K (-30%).
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Sleep Testing Services | $2.4M | $844K | $1.5M | +183% |
| Tooth Positioners | $715K | $857K | −$142K | -17% |
| Appliances | $640K | $1.0M | −$388K | -38% |
| Myofunctional Therapy Services | $337K | $163K | $174K | +107% |
| Sponsorship Seminar Other | $161K | $608K | −$447K | -74% |
| Billing Intelligence Services | $129K | $190K | −$61K | -32% |
| VIP | $12K | $130K | −$118K | -91% |
| Product | $1.4M | $1.9M | −$594K | -30% |
| Revenue | $5.2M | $3.8M | $1.3M | +35% |
| Net loss | $5.5M | $5.0M | $510K | +10% |
| Costs & expenses | $10.7M | $8.8M | $1.8M | +21% |
| Operating costs | $10.0M | $8.7M | $1.3M | +15% |
| Interest & other, net | $698K | $148K | $550K | +372% |
| Cost of revenue | $2.2M | $1.7M | $490K | +29% |
| Sales & marketing | $155K | $260K | −$105K | -40% |
| General & admin | $7.1M | $6.4M | $704K | +11% |
| Other operating costs | $510K | $306K | $204K | +67% |
| Operating cash sources | $5.5M | $5.0M | $510K | +10% |
| Depreciation & amortization | $510K | $306K | $204K | +67% |
| Share-based compensation | $50K | $242K | −$192K | -79% |
| Working capital & other | $1.8M | $971K | $844K | +87% |
| Cash used in operations | $3.1M | $3.5M | −$346K | -10% |
| Net loss absorbed | $5.5M | $5.0M | $510K | +10% |
Questions
How much did Vivos Therapeutics's revenue grow year over year in Q2 2026?
Vivos Therapeutics's revenue rose $1.3M (+35%) from $3.8M in Q2 2025 to $5.2M in Q2 2026.
What drove Vivos Therapeutics's revenue change in Q2 2026?
Product −$594K (-30%).